Following on from information provided to NICE by the company in June 2014, the appraisal of Neuroblastoma (high-risk) – dinutuximab, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 799
- Referral date:
- 01 March 2015
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics – York
Stakeholders
- Companies sponsors
- United Therapeutics (dinutuximab)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- Children’s Cancer and Leukaemia Group
- Neuroblastoma UK
- Solving Kids Cancer
- Professional groups
- Cancer Research UK
- Royal College of Nursing
- Royal College of Paediatrics and Child Health
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Alliance Pharma (isotretinoin) (CA&U not returned, not participating)
- Roche (isotretinoin)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Relevant research groups
- National Cancer Research Institute
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2014, the appraisal of Neuroblastoma (high-risk) – dinutuximab, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 February 2017 | Note added to the project documents |
| 17 February 2017 | Suspended. See note |
| 29 November 2016 | Appeal decision |
| 30 September 2016 | Appeal |
| 07 July 2016 - 28 July 2016 | Final appraisal determination: 2 |
| 26 May 2016 | Committee meeting: 3 |
| 05 May 2016 | Note added to the project documents |
| 14 April 2016 | Note added to the project documents |
| 27 January 2016 | Committee meeting: 2 |
| 05 November 2015 - 25 November 2015 | Draft guidance |
| 06 October 2015 | Committee meeting: 1 |
| 07 May 2015 | Invitation to participate |
For further information on our processes and methods, please see our CHTE processes and methods manual